NVT102 is the Super TLR3 agonist with strong biological and translational potential. It is a patented biologic formulation that is lipolyzed, highly stable (maintained at 4°C for over two years), and demonstrates consistent immune activation across species from mouse to human. The potency has been improved by thousands of times compared to other TLR3 agonists.

The platform has been experimentally validated as a vaccine adjuvant in multiple settings, including Influenza, RSV, and Zoster vaccines, where it enhances both humoral and cellular immune responses. Compared to standard adjuvants, NVT102 significantly increases antigen-specific antibody production, neutralizing activity, and T cell responses in preclinical models.

In RSV vaccine studies, NVT102 showed superior immunogenicity, with markedly higher IgG titers and neutralizing antibody levels, as well as enhanced CD4+ and CD8+ T cell activation. Importantly, these effects were achieved without significant toxicity, as indicated by stable body weight profiles following vaccination.

Similarly, in Zoster vaccine models, NV102 improved both antibody responses and CD4+ T cell immunity in both priming and non-priming conditions, demonstrating robust adjuvant activity across different immunization settings. Safety assessments further confirmed acceptable tolerability.

In influenza vaccine models, NVT102 shows a dramatic antigen-sparing effect, requiring less than 30-fold antigen for the corresponding IgG responses, T-cell responses, and the HAI assay.

From a development perspective, NVT102 is supported by GMP manufacturing with CMC readiness, enabling production of up to multi-million doses with no apparent scalability limitations. The platform is currently undergoing preclinical safety evaluation, including non-human primate studies, with completion targeted by November 2026.

Overall, NVT102 represents a scalable and versatile adjuvant platform capable of enhancing both adaptive and cellular immunity, with broad applicability across infectious diseases and immunotherapy. It can be formulated your choice of vaccine adjuvant both for the high demanded as well as LMIC markets.